Prima BioMed Ltd., a globally active biotechnology company, has commenced recruitment of patients into the CANVAS (CANcer VAccine Study) trial in Europe. Prima has authorized several centers in Ukraine to start enrolling patients.
CANVAS is a phase II/III study of CVac for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer patients who achieve remission after optimal debulking surgery and standard first line chemotherapy.
Prima has obtained the requisite ethics and regulatory approvals in multiple European countries, including Belarus, Belgium, Bulgaria, Germany, Lithuania, Latvia, Poland and Ukraine. The company anticipates that the majority of CANVAS patients will be enrolled in Europe. The trial is currently open for recruitment at a number of centers in the United States and Australia.
Prima BioMed CEO Matthew Lehman said, “We are pleased to open enrollment for the CANVAS trial in Europe; we plan to progressively open sites across several European countries in the coming months. I would like to congratulate our clinical team and our manufacturing colleagues at the Fraunhofer Institute of Cell Therapy and Immunology for bringing us to this milestone.”
The CANVAS is a multi-centre, randomized, and placebo-controlled study of CVac in mucin 1 positive, epithelial ovarian cancer patients who have undergone optimal surgery and achieve complete remission after first-line chemotherapy. 1000 patients will be recruited to CANVAS at over 100 hospitals throughout Australia, the USA, Europe, and Asia to have 800 evaluable study patients undergo dosing.
The study objectives are to ascertain if CVac, as compared to a placebo, is able to improve the time patients remain in remission before tumor progression (progression-free survival) and extend overall survival of patients. Safety parameters, quality of life impact, manufacturing quality, and additional laboratory assessments will also be investigated.
Prima BioMed is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders.